Subcutaneous infliximab CT-P13 without intravenous induction in psoriatic arthritis: A case report and pharmacokinetic considerations.
Int J Clin Pharmacol Ther
; 62(3): 122-125, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-38214148
ABSTRACT
INTRODUCTION:
The biosimilar CT-P13, the first and only subcutaneous (SC) infliximab formulation, is recommended for patients with psoriatic arthritis (PsA) and can be administered as a maintenance treatment, to be started 4 weeks after the induction treatment with 2 intravenous (IV) infliximab infusions.OBJECTIVE:
To evaluate treatment with SC infliximab without prior IV infusion induction to meet patient needs. MATERIALS ANDMETHODS:
After approval by the ethics review board and based on the schedule approved for rheumatoid arthritis, SC induction was performed with infliximab CT-P13 120 mg weekly for 4 weeks, followed by an injection of 120 mg every 2 weeks.RESULTS:
After 4 months of therapy, joint symptoms were resolved, inflammation parameters were normalized (erythrocyte sedimentation rate) reduced from 42 to 16 mm/h, and C-reactive protein from 1.74 to 0.43 mg/dL), and clinical assessment parameters were improved. After 9 months of therapy, the clinical data remained stable, with no adverse events or local side effects.CONCLUSION:
SC infliximab was successfully used without previous IV infusion induction. Although, to date, the induction of PsA treatment via the SC route is not foreseen, the known pharmacokinetic properties and the outcome improvements observed in our patient show that subcutaneous treatment induction, as is already done in the treatment of rheumatoid arthritis, is also possible.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Artrite Reumatoide
/
Artrite Psoriásica
/
Medicamentos Biossimilares
/
Anticorpos Monoclonais
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article